Global Microbial API Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for Microbial API Market is presumed to reach the market size of nearly USD 105.09 BN by 2030 from USD 60.21 BN in 2022 with a CAGR of 7.21% under the study period 2023 - 2030.

Microbial API refers to Active Pharmaceutical Ingredients derived from microorganisms, such as bacteria, fungi, or other microorganisms. These APIs are the core therapeutic components in medications that exert a pharmacological effect on the body.

MARKET DYNAMICS:

The microbial API market's growth is driven by multiple interconnected factors. Heightened demand for antibiotics due to increasing infections and antibiotic resistance propels the need for microbial-derived APIs. Technological advancements, particularly in biotechnology and genetic engineering, have revolutionized microbial fermentation, making it more efficient and cost-effective for producing complex APIs. The pharmaceutical industry's expansion and pursuit of innovative drugs contribute significantly to the demand for diverse microbial APIs, especially as the focus on biopharmaceuticals intensifies. Government regulations supporting drug safety and efficacy, alongside initiatives promoting new drug development, positively influence this market. Collaborations between pharmaceutical firms and research institutions, coupled with substantial investments in R&D, accelerate microbial API discovery and production. The market's expansion in emerging economies, driven by increased healthcare spending and awareness, further fuels the demand for affordable medications. Additionally, the environmental sustainability of microbial API production methods has led to their preference over traditional chemical synthesis, fostering a promising future for microorganism-based pharmaceutical manufacturing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of microbial api. The growth and trends of microbial api industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the microbial api market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Host

Mammalian
Bacterial
Fungal

By Type

Antibody
Peptide
Protein
Small Molecule
Vaccine

By Site

In-House
Outsourced

By End-Use

Pharmaceutical Companies
Biopharmaceutical Companies
Others

By Molecule

Innovative
Generic

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Microbial API market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Microbial API market include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112866

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MICROBIAL API - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Host
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Site
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Molecule
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MICROBIAL API MARKET ANALYSIS BY HOST

5.1 Overview by Host
5.2 Historical and Forecast Data
5.3 Analysis by Host
5.4 Mammalian Historic and Forecast Sales by Regions
5.5 Bacterial Historic and Forecast Sales by Regions
5.6 Fungal Historic and Forecast Sales by Regions

6 . GLOBAL MICROBIAL API MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Antibody Historic and Forecast Sales by Regions
6.5 Peptide Historic and Forecast Sales by Regions
6.6 Protein Historic and Forecast Sales by Regions
6.7 Small Molecule Historic and Forecast Sales by Regions
6.8 Vaccine Historic and Forecast Sales by Regions

7 . GLOBAL MICROBIAL API MARKET ANALYSIS BY SITE

7.1 Overview by Site
7.2 Historical and Forecast Data
7.3 Analysis by Site
7.4 In-house Historic and Forecast Sales by Regions
7.5 Outsourced Historic and Forecast Sales by Regions

8 . GLOBAL MICROBIAL API MARKET ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Pharmaceutical Companies Historic and Forecast Sales by Regions
8.5 Biopharmaceutical Companies Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL MICROBIAL API MARKET ANALYSIS BY MOLECULE

9.1 Overview by Molecule
9.2 Historical and Forecast Data
9.3 Analysis by Molecule
9.4 Innovative Historic and Forecast Sales by Regions
9.5 Generic Historic and Forecast Sales by Regions

10 . GLOBAL MICROBIAL API MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE MICROBIAL API COMPANIES

11.1. Microbial Api Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF MICROBIAL API INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Merck & Co. Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Topfond Pharmaceutical Co. Ltd.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. DSM
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. CSPC Pharmaceutical Group Limited
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. KOLON LIFE SCIENCE
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Shandong Lukang Pharmaceutical Co. Ltd.
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Teva Pharmaceutical Industries Ltd.
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Lonza
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies